The High-Sensitivity Modified Glasgow Prognostic Score Is Superior to the Modified Glasgow Prognostic Score as a Prognostic Predictor in Patients with Resectable Gastric Cancer

104 Background: Modified Glasgow Prognostic Score (mGPS), based on serum C-reactive protein (CRP) and albumin-levels, was reported to be a good prognosticator for survival in patients with lung cancer. However, the role of mGPS in gastric cancer is still controversial. The aim of this study is to clarify the significance of mGPS as a prognosticator in patients with gastric cancer. Methods: This study included 1,062 patients who underwent gastrectomy for gastric cancer at Shizuoka Cancer Center between September 2002 and December 2006. Patients who received neoadjuvant chemotherapy, and those who had other cancers were excluded from the analysis. mGPS is defined by serum CRP level and serum albumin level. Patients with serum CRP level of 1.0mg/dl or lower were classified to mGPS 0 irrespective to the serum albumin level. Patients with elevated serum CRP level (>1.0mg/dl) were classified to mGPS1 or mGPS2 according to the serum albumin level (mGPS1, albumin≥3.5g/dl; mGPS2, albumin<3.5g/dl). We compared relationships between mGPS and clinicopathological characteristics of patients, the incidence of intra-abdominal infectious complications (Clavien-Dindo grade II or more severe), and overall survival. Results: There were 712 male and 350 female patients. The median age was 65 years old. The number of patients classified to the mGPS0, mGPS1, and mGPS2 group were 970 (91.3%), 59 (5.6%), and 33 (3.1%), respectively. The incidences of intra-abdominal infectious complications were 27.1% in mGPS1, and 24.3% in mGPS2, and were significantly higher than that in mGPS0 (9.5%, P< 0.001). Overall five-year survival rates were 74.6% in mGPS0, 61.4% in mGPS1, and 34.6% in mGPS2. The overall survival was significantly worse in patients with mGPS2 than those with mGPS0 or mGPS1 (P<0.001). Conclusions: mGPS was correlated with the incidence of intra-abdominal infectious complications. In addition, mGPS was found to be a prognosticator for survival in patients with gastric cancer. Preoperative nutritional support may lead to reduced incidence of surgical complications and improved survival outcome after gastrectomy in patients with gastric cancer.

Download Full-text

Utility of the High-Sensitivity Modified Glasgow Prognostic Scores for Oropharyngeal Carcinoma

OTO Open ◽

10.1177/2473974x211042302 ◽

2021 ◽

Vol 5 (3) ◽

pp. 2473974X2110423

Author(s):

Hiroyuki Iuchi ◽

Junichiro Ohori ◽

Yumi Ando ◽

Takeshi Tokushige ◽

Megumi Haraguchi ◽

...

Keyword(s):

Prognostic Score ◽

Performance Status ◽

Univariate Analysis ◽

Multivariable Analysis ◽

Glasgow Prognostic Score ◽

Disease Free Survival ◽

High Sensitivity ◽

Prognostic Scores ◽

Albumin Concentration ◽

Modified Glasgow Prognostic Score

Objective There is increasing evidence that the high-sensitivity modified Glasgow prognostic scores are inflammatory indices that can predict survival for many cancer types. However, there is limited information regarding their prognostic values in cases of head and neck cancer. This study aimed to evaluate whether the high-sensitivity modified Glasgow prognostic scores could predict outcomes among patients with oropharyngeal squamous cell carcinoma (OPC). Study Design Retrospective study. Setting University hospital. Methods We reviewed the records of 106 patients with histologically confirmed OPC between March 2009 and June 2020. The high-sensitivity modified Glasgow prognostic scores were calculated as 0 (C-reactive protein [CRP] concentration: ≤0.3 mg/dL), 1 (CRP concentration >0.3 mg/dL and albumin concentration ≥3.5 mg/dL), or 2 (CRP concentration >0.3 mg/dL and albumin concentration <3.5 mg/dL). Univariate and multivariable Cox proportional hazard analyses were performed for overall survival (OS) and disease-free survival (DFS). Results Forty-four of these patients had human papillomavirus (HPV)–positive OPC, and 62 had HPV-negative OPC, and these populations were analyzed separately. The high-sensitivity modified Glasgow prognostic score was significantly associated with age, performance status, and HPV. On univariate analysis, high-sensitivity modified Glasgow prognostic score showed associations with OS and DFS in both subpopulations. Moreover, on multivariable analysis, the high-sensitivity modified Glasgow prognostic score showed associations with OS and DFS in both subpopulations. Poor performance status predicted OS in both subpopulations. Conclusion We conclude that the high-sensitivity modified Glasgow prognostic score is useful as an independent prognostic factor in OPC.

Download Full-text

The prognostic role of the preoperative systemic immune-inflammation index and high-sensitivity modified Glasgow prognostic score in patients after radical operation for soft tissue sarcoma

European Journal of Surgical Oncology ◽

10.1016/j.ejso.2020.05.026 ◽

2020 ◽

Vol 46 (8) ◽

pp. 1496-1502

Author(s):

Tao Hou ◽

Tianhui Guo ◽

Runcong Nie ◽

Dongchun Hong ◽

Zhiwei Zhou ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Prognostic Score ◽

Glasgow Prognostic Score ◽

High Sensitivity ◽

Radical Operation ◽

Prognostic Role ◽

Modified Glasgow Prognostic Score ◽

Immune Inflammation

Download Full-text

Modified Glasgow prognostic score, prognostic nutritional index and ECOG score could be new prognostic factors for survival in metastatic gastric cancer

Annals of Oncology ◽

10.1093/annonc/mdx369.049 ◽

2017 ◽

Vol 28 ◽

pp. v226

Author(s):

B. Demirelli ◽

N. Babacan ◽

S. Koca ◽

B.N. Uzun ◽

Ö. Ercelep ◽

...

Keyword(s):

Gastric Cancer ◽

Prognostic Factors ◽

Prognostic Score ◽

Glasgow Prognostic Score ◽

Prognostic Nutritional Index ◽

Metastatic Gastric Cancer ◽

Modified Glasgow Prognostic Score ◽

Nutritional Index

Download Full-text

Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel

Cancers ◽

10.3390/cancers13040773 ◽

2021 ◽

Vol 13 (4) ◽

pp. 773

Author(s):

Keisuke Ando ◽

Shinichi Sakamoto ◽

Shinpei Saito ◽

Maihulan Maimaiti ◽

Yusuke Imamura ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Prognostic Score ◽

Glasgow Prognostic Score ◽

High Sensitivity ◽

Hazard Ratio ◽

Castration Resistant Prostate Cancer ◽

Modified Glasgow Prognostic Score ◽

Castration Resistant ◽

Docetaxel Treatment

The Glasgow prognostic score, a marker of systemic inflammation, is associated with clinical outcomes in different cancers including prostate cancer. However, there is no evidence for the relationship between the high-sensitivity modified Glasgow prognostic score (Hs-mGPS) in prostate cancer and its prognosis. This study aimed to investigate the prognostic significance of Hs-mGPS in castration-resistant prostate cancer (CRPC) treated with docetaxel. We retrospectively analyzed clinical datasets from 131 CRPC patients who received docetaxel treatment at Chiba University Hospital and a related hospital. Clinical factors including Hs-mGPS before docetaxel treatment were evaluated according to overall survival. The numbers of patients with Hs-mGPS of 0, 1, and 2 were 88, 30, and 13, respectively. The median prostate-specific antigen (PSA) level was 28.9 ng/mL. The median testosterone level was 13.0 ng/dL. The percentages of bone and visceral metastases were 80.8% and 10.2%, respectively. For overall survival, Hs-mGPS ≥ 1 (hazard ratio of 2.41; p = 0.0048), testosterone ≥ 13.0 ng/dL (hazard ratio of 2.23; p = 0.0117), and PSA ≥ 28.9 ng/mL (hazard ratio of 2.36; p = 0.0097) were significant poor prognostic factors in the multivariate analysis. The results of the two-group analysis showed that a higher Hs-mGPS was associated with high PSA, alkaline phosphatase, and testosterone levels. The median testosterone levels for Hs-mGPS of 0, 1, and 2 were 9.0, 16.5, and 23.0, respectively. Based on the multivariate analysis, we created a combined score with three prognostic factors: Hs-mGPS, testosterone, and PSA. The low-risk group (score of 0–1) showed a significantly longer overall survival compared to the intermediate-risk (score of 2–3) and high-risk (score of 4) groups (p < 0.0001). Our results demonstrated that an elevated Hs-mGPS was an independent prognostic factor in CRPC patients treated with docetaxel therapy. Risk classification based on Hs-mGPS, testosterone, and PSA may be useful in predicting the prognosis of CRPC patients.

Download Full-text